Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antigen-specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jun, Chehrazi-Raffle, Alexander, Reddi, Srikanth, Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778665/
https://www.ncbi.nlm.nih.gov/pubmed/29357948
http://dx.doi.org/10.1186/s40425-018-0316-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778665/
https://www.ncbi.nlm.nih.gov/pubmed/29357948
http://dx.doi.org/10.1186/s40425-018-0316-z

Ejemplares similares